Peptides for Acute Kidney Injury Protection

Peptide Kidney Therapeutics

13.3M cases/year

Acute kidney injury affects 13.3 million people annually and kills 1.7 million, yet no approved drug specifically treats it. Peptides are the most active area of preclinical research.

Multiple sources, 2020-2026

Multiple sources, 2020-2026

View as image

Acute kidney injury (AKI) strikes 13.3 million people worldwide each year and contributes to 1.7 million deaths. It occurs when the kidneys abruptly lose their filtering capacity, triggered by ischemia during surgery, sepsis, or nephrotoxic drugs like cisplatin. Despite decades of research, no drug specifically treats AKI. Management remains supportive: fluids, hemodynamic optimization, and dialysis when filtration fails entirely. Peptide therapeutics offer the most diverse preclinical pipeline for AKI, targeting mitochondrial dysfunction, inflammation, ferroptosis, and fibrotic scarring. For a broader view of how peptides are being developed across kidney conditions, see our pillar article on peptide therapeutics for chronic kidney disease.

Why Kidneys Are Vulnerable to Acute Injury

The kidneys filter approximately 180 liters of blood daily, consuming more oxygen per gram of tissue than nearly any other organ. Renal tubular epithelial cells, particularly in the proximal tubule, are packed with mitochondria to power the ion transport that drives filtration. This dependence on oxidative metabolism makes them exquisitely sensitive to ischemia, toxic insults, and sepsis-related hemodynamic collapse.

When blood flow drops during surgery or septic shock, tubular cells lose ATP within minutes. Mitochondria generate reactive oxygen species (ROS) as electron transport stalls. When blood flow returns (reperfusion), the ROS burst intensifies, triggering a cascade: NLRP3 inflammasome activation, IL-1beta release, neutrophil infiltration, and tubular cell death through apoptosis and ferroptosis. The initial injury often progresses to chronic kidney disease if fibrotic scarring replaces functional tissue.

Peptide therapeutics target each node in this cascade. Mitochondria-targeted peptides address the energy failure at the source. Anti-inflammatory peptides suppress the secondary immune damage. Anti-fibrotic peptides prevent the long-term scarring that converts acute injury into permanent kidney loss.

SS-31 (Elamipretide): Protecting Mitochondria From the Inside

SS-31 is a four-amino-acid peptide (D-Arg-Dmt-Lys-Phe-NH2) that concentrates in the inner mitochondrial membrane by binding to cardiolipin, a phospholipid critical for electron transport chain function. It is the most extensively studied peptide in AKI preclinical research.

In a landmark study, Szeto and colleagues demonstrated that SS-31 accelerated ATP recovery and reduced ischemic kidney injury in rats. The peptide preserved mitochondrial membrane potential, prevented cytochrome c release, and reduced tubular cell apoptosis. Importantly, SS-31 was effective even when administered after the ischemic insult, suggesting a therapeutic window beyond prevention.^[1]

Subsequent work extended these findings to cisplatin-induced AKI, a major clinical problem in cancer patients receiving chemotherapy. Yang and colleagues showed that SS-31 suppressed mitochondrial ROS generation, which in turn blocked NLRP3 inflammasome activation. The peptide decreased NLRP3, IL-1beta, and caspase-1 expression in both cisplatin-treated mice and HK-2 human kidney cells, protecting against tubular injury through the mitochondrial ROS-NLRP3 axis.^[2]

A third study engineered SS-31-loaded nanoparticles with pH-responsive and AKI-kidney targeting properties. The nanoparticle formulation accumulated preferentially in injured kidneys and enhanced the peptide's protective effects compared to free SS-31.^[3] This targeting approach addresses a practical limitation: systemically administered SS-31 distributes to all mitochondria-rich tissues, not just injured kidneys. For more on how peptides are being engineered for kidney-targeted drug delivery, see our dedicated article.

SS-31 (branded as elamipretide) has entered clinical trials for other mitochondrial conditions, including Barth syndrome and heart failure. No human AKI trial has been completed, though the preclinical evidence base is among the strongest for any peptide in nephrology.

Thymosin Beta-4: A Biomarker and Potential Protector

Thymosin beta-4 (Tbeta4) has a dual role in AKI: it functions as both a prognostic biomarker and a potential therapeutic. In a prospective observational cohort of 191 sepsis patients, Zhang and colleagues measured serum Tbeta4 concentrations and tracked kidney outcomes. Patients in the lowest Tbeta4 tertile (1.19-7.11 ng/mL) had significantly higher rates of AKI, with an odds ratio of 2.102 per stage decrease (95% CI 1.448-3.050, p<0.001). Lower Tbeta4 also predicted need for continuous renal replacement therapy and higher 28-day mortality.^[4]

This observational finding gained mechanistic support from interventional animal studies. Aksu and colleagues tested exogenous Tbeta4 in a rat model of ischemic AKI, comparing pre-treatment (before clamping the renal artery) and peri-ischemic treatment (during ischemia). Both protocols significantly reduced serum creatinine and blood urea nitrogen (p<0.001). Tbeta4 decreased caspase-9 and MMP-9 activity, reduced hyaluronan and oxidative stress markers, and restored antioxidant enzyme levels.^[5]

A 2026 review in Peptides characterized Tbeta4 and its derivative Ac-SDKP as "emerging therapeutic candidates for kidney diseases," noting cytoprotective, anti-inflammatory, and antifibrotic effects across multiple AKI and CKD models. The review also flagged an important caveat: Tbeta4 has bidirectional effects on fibrosis that depend on the model and context, sometimes promoting and sometimes inhibiting fibrotic pathways.^[6]

This ambiguity matters. In AKI, some degree of fibrotic repair is necessary for tissue healing. A peptide that blocks all fibrotic signaling could impair recovery. The therapeutic window for Tbeta4, both in timing and in the balance between pro-healing and anti-scarring effects, has not been defined.

GLP-1 Receptor Agonists: Metabolic Drugs With Kidney-Protective Effects

GLP-1 receptor agonists, developed for diabetes and obesity, have demonstrated kidney-protective properties across multiple clinical and preclinical settings. A 2020 review synthesized the evidence, noting that these peptides reduce macro-albuminuria in cardiovascular safety trials through anti-inflammatory, hemodynamic, and metabolic mechanisms.^[7]

The AKI-specific evidence is newer and more mechanistic. Liraglutide protected against cisplatin-induced AKI in mice by activating NRF2, the master transcription factor for antioxidant defense. The peptide enhanced NRF2 through both KEAP1-dependent and KEAP1-independent pathways, reducing iron accumulation and lipid peroxidation, the hallmarks of ferroptosis. This represents a specific anti-ferroptotic mechanism rather than general anti-inflammatory activity.^[8]

In a separate study of renal ischemia-reperfusion injury, liraglutide alleviated kidney damage by inhibiting macrophage extracellular trap (MET) formation. The peptide decreased STAT1 phosphorylation and increased STAT3/6 phosphorylation, promoting M2 (anti-inflammatory) macrophage polarization over M1 (pro-inflammatory). When STAT3/6 was pharmacologically inhibited, liraglutide's protective effects were abolished, confirming this as a primary mechanism.^[9]

A 2026 retrospective study examined whether preoperative GLP-1 RA exposure affected postoperative AKI risk after bariatric surgery. GLP-1 RA use was not associated with increased AKI risk, providing some reassurance about perioperative safety, though the study was not designed to detect a protective effect.^[10]

The GLP-1 kidney data have a significant limitation: these drugs were developed for metabolic disease, and every human kidney study involves patients with diabetes or obesity. Whether the nephroprotective effects are direct (GLP-1 receptors on kidney cells) or indirect (improved metabolic health reducing kidney stress) is not fully resolved. Animal studies suggest both contribute, but isolating the direct renal effect in humans remains challenging.

GHRP-6: A Self-Assembling Peptide Hydrogel for AKI

Growth hormone-releasing peptide 6 (GHRP-6) has been explored as an AKI therapy through an innovative delivery format. Zhao and colleagues designed a self-assembling GHRP-6 peptide hydrogel hypothesized to reprogram the metabolism of renal tubular epithelial cells damaged by ischemia. Metabolomic analysis revealed enrichment of compounds involved in amino acid metabolism and fatty acid oxidation, two pathways disrupted in AKI.^[11]

The hydrogel format offers sustained local release, avoiding the rapid clearance that limits most peptide therapeutics. By forming a depot at the injection site, the GHRP-6 hydrogel provides continuous peptide exposure during the critical injury and recovery window. The metabolic reprogramming mechanism is distinct from the anti-inflammatory or antioxidant pathways targeted by other AKI peptides, potentially offering a complementary therapeutic approach.

This remains a single preclinical study from one research group. The metabolic reprogramming concept is intriguing but has not been replicated or tested in larger animal models.

BPC-157: Distant Organ Protection in Ischemia

BPC-157, a 15-amino-acid peptide derived from gastric juice, has been studied for protection against distant organ damage, including kidney injury, during lower-extremity ischemia-reperfusion. Demirtas and colleagues showed that BPC-157 reduced histological markers of kidney damage in rats subjected to experimental limb ischemia, suggesting the peptide may protect kidneys from the systemic inflammatory response that accompanies major surgical procedures.^[12]

The BPC-157 kidney evidence is thin compared to other peptides in this review. The study measured histological endpoints without detailed mechanistic analysis, and BPC-157's mechanism of action in kidney tissue is not well characterized. This area needs substantially more work before any conclusions about renal protection can be drawn. For context on BPC-157's broader research profile, see how BPC-157 may protect the gut lining.

Kidney-Targeting Peptide Libraries: A 2025 Breakthrough

A 2025 study published in Science Advances took a systematic approach to the targeting problem. Researchers constructed a library of 1,885 peptides designed to bind kidney injury molecule-1 (KIM-1), a receptor upregulated on injured proximal tubular cells. Through computational screening and experimental validation, they identified TKP-4, a peptide that efficiently targeted injured renal cells both in vitro and in vivo. When TKP-4-decorated liposomes were loaded with a renal-protective compound, they accumulated preferentially in injured kidneys and alleviated AKI significantly better than untargeted delivery.

This work represents a platform advance rather than a single drug candidate. By establishing a validated method for identifying kidney injury-targeting peptides, the study enables any AKI therapeutic, peptide or otherwise, to be delivered preferentially to injured tissue. The practical impact depends on whether TKP-4 targeting translates to larger animal models and human kidney injury, where the heterogeneity of damage patterns may complicate targeted delivery.

Cell-Permeable Antioxidant Peptides

An earlier but foundational study demonstrated that cell-permeable antioxidant peptides could reduce renal tubular apoptosis. Mizuguchi and colleagues tested a novel peptide in a rat model of unilateral ureteral obstruction (UUO), showing decreased renal tubular apoptosis and damage. The peptide penetrated cell membranes and scavenged intracellular ROS, protecting tubular cells from oxidative death.^[13]

This study established the principle that peptides engineered for cell penetration and antioxidant activity can reach intracellular compartments in kidney tissue, providing the conceptual foundation for subsequent work with SS-31 and other mitochondria-targeted designs.

Where AKI Peptide Research Stands

The peptide pipeline for AKI is preclinically rich but clinically empty. No peptide has completed a human trial specifically for acute kidney injury. SS-31 (elamipretide) is the closest to clinical translation, with human data in other mitochondrial conditions, but an AKI-specific trial has not been initiated. GLP-1 agonists have extensive human kidney data, but all of it comes from diabetic or obese populations, and the AKI-specific mechanistic evidence is entirely from animals.

The field's most pressing need is not more preclinical studies but rather clinical translation. Multiple peptides, SS-31, thymosin beta-4, and GLP-1 agonists, have consistent evidence across different AKI models (ischemia-reperfusion, cisplatin, sepsis). The question is no longer whether peptides can protect kidneys in rodents. It is whether the effects are large enough, fast enough, and safe enough to matter in the intensive care unit.

The Bottom Line

Peptide therapeutics for acute kidney injury target mitochondrial dysfunction (SS-31), inflammation and apoptosis (thymosin beta-4), ferroptosis (liraglutide), and metabolic reprogramming (GHRP-6). SS-31 has the deepest preclinical evidence across ischemic and cisplatin AKI models. Thymosin beta-4 serves dual roles as a prognostic biomarker in sepsis-associated AKI and a therapeutic candidate. GLP-1 agonists protect kidneys through anti-ferroptotic and macrophage-polarizing mechanisms. Despite this breadth of preclinical data, no peptide has entered a human trial specifically for AKI, leaving the 13.3 million annual cases without a targeted pharmaceutical treatment.

Frequently Asked Questions

What peptides protect kidneys from acute injury?

SS-31 (elamipretide), thymosin beta-4, and GLP-1 receptor agonists (liraglutide, exenatide) have the strongest preclinical evidence for kidney protection during acute injury. SS-31 targets mitochondrial dysfunction by binding cardiolipin, thymosin beta-4 reduces apoptosis and oxidative stress, and GLP-1 agonists suppress ferroptosis and promote anti-inflammatory macrophage polarization. All evidence comes from animal models; no peptide has completed a human AKI trial.

Does SS-31 work for kidney injury?

SS-31 (elamipretide) accelerated ATP recovery and reduced apoptosis in ischemic kidney injury models. It also blocked NLRP3 inflammasome activation in cisplatin-induced AKI by suppressing mitochondrial ROS. SS-31 has entered human clinical trials for mitochondrial diseases like Barth syndrome and heart failure, but no human trial has tested it specifically for acute kidney injury.

Can GLP-1 drugs prevent kidney damage?

GLP-1 receptor agonists reduce albuminuria and slow kidney function decline in patients with type 2 diabetes, based on large cardiovascular outcome trials. In animal models of AKI, liraglutide protected kidneys by activating NRF2 antioxidant pathways and promoting M2 macrophage polarization. A key limitation is that all human kidney data comes from diabetic populations, so the direct renal protective effect independent of metabolic improvement is not fully established.

What is thymosin beta-4 and kidney disease?

Thymosin beta-4 is a 43-amino-acid peptide involved in cell migration, anti-inflammation, and tissue repair. In sepsis patients, lower serum thymosin beta-4 levels predicted acute kidney injury with an odds ratio of 2.1 per stage (p<0.001). In rat models, exogenous thymosin beta-4 reduced creatinine, BUN, and oxidative stress markers during ischemic AKI. A 2026 review called it an "emerging therapeutic candidate" but noted bidirectional effects on fibrosis.

Why is there no drug treatment for acute kidney injury?

AKI involves multiple simultaneous injury pathways: ischemia, oxidative stress, inflammation, and cell death. Single-target drugs have repeatedly failed in clinical trials because blocking one pathway is insufficient. The heterogeneity of AKI causes (surgery, sepsis, drugs, contrast agents) makes trial design difficult, and the speed of onset limits the therapeutic window. Peptides targeting upstream events like mitochondrial dysfunction may have broader effects, but none has yet been tested in human AKI trials.

Is BPC-157 good for kidneys?

One study found that BPC-157 reduced histological markers of kidney damage in rats subjected to lower-extremity ischemia-reperfusion injury. The evidence is extremely limited: a single animal study without detailed mechanistic analysis. BPC-157's mechanism of action in kidney tissue has not been characterized. No human kidney data exist for BPC-157.